Treatment of Cognitive Deficits in Multiple Sclerosis With High-Defini
Treatment of Cognitive Deficits in Multiple Sclerosis With High-Definition Transcranial Direct Current Stimulation
What it found
No result yet.
What was tested
Treatment tested
- Transcranial Direct Current Stimulation
Placebo
- Sham transcranial direct current stimulation
What it measured
Main measures
Treatment group differences in change from Baseline to 1-week Post-Treatment on Category Fluency
Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-months Post-Treatment on Category Fluency
Outcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-month Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-Treatment on COWAT
Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 2-months Post-Treatment on COWAT
Outcome measures will be assessed as change over a period of 13 weeks: Change from baseline to 2-months Post-Treatment
Other measures (30)
Treatment group differences in change from Baseline to 1-week Post-Treatment on the Trail Making Test (Part A)
Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-Treatment on the Trail Making Test (Part B)
Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-Treatment on the Delis Kaplan Color Word Interference Test
Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-Treatment on on the Digit Span Forward
Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Thinking and memoryTreatment group differences in change from Baseline to 1-week Post-Treatment on the Digit Span Backward
Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Thinking and memoryTreatment group differences in change from Baseline to 1-week Post-Treatment on on the the Rey-Osterrieth Complex Figure Test
Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-Treatment on the Digit Symbol Substitution Test
Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-Treatment on the Grooved Pegboard Test
Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-Treatment on the Semantic Object Retrieval Test
Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Treatment group differences in change from Baseline to 1-week Post-Treatment on the Boston Naming Test
Outcome measures will be assessed as change over a period of 6 weeks: Change from baseline to 1-week Post-Treatment
Who could take part
Relapsing MS · 18 to 65
Show the full criteria
Inclusion criteria
º Diagnosed with relapsing-remitting multiple sclerosis (RRMS) º Memory retrieval deficit based on neuropsychological testing done in our lab º Must be fluent in speaking and reading English.
Exclusion criteria
º Relapse or acute MS exacerbation or a course of steroids in the two months preceding the testing º Participants using benzodiazepines must have been on a stable dose for at least two months º Potentially confounding psychological or neurological disorder, including: * dementia of any type * epilepsy or other seizure disorders * severe traumatic brain injury * brain tumor * present drug abuse * stroke * blood vessel abnormalities in the brain * Parkinson's disease * Huntington's disease º inability to give informed consent º cranial implants º skull defects that affect tDCS administration º use of medications that interact with or potentially interact with tDCS effects, including: * anti-convulsants * L-dopa * carbamazepine * sulpiride * pergolide * lorazepam * rivastigmine * dextromethorphan * D-cycloserine * flunarizine * ropinirole * stimulants (dextroamphetamine/amphetamine/modafinil/armodafinil) must be stopped during enrollment
As registered. Criteria can change, so ask the trial team or your neurologist.
Contact details on the registryAbout this trial
In the sponsor's words
The purpose of the study is to test whether low level electric stimulation, called transcranial Direct Current Stimulation (tDCS), on the part of the brain (i.e., presupplementary motor area) thought to aid in memory will improve verbal retrieval in multiple sclerosis patients. The primary outcome measures are neuropsychological assessments of verbal retrieval, and the secondary measures are neuropsychological assessments of other cognitive abilities and electroencephalography (EEG) measures. Additionally, the study will examine the degree to which baseline assessments of cognition and concussion history predict responses to treatment over time, both on assessments administered within the intervention period and at follow-up.
Loading reviews and guidelines…
History
Started
Oct 2023
Main results due
Jun 2027
Finished
Jun 2027